Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferdinando De Vita

Showing results (1-10 of 162) with videos related to

Pageof 17
Sort By:
Expert Opinion on Investigational Drugs|May 27, 2009
Novel investigational drugs for gastric cancerLoredana Vecchione, Michele Orditura, Fortunato Ciardiello, et al.
Current Opinion in Oncology|April 13, 2004
The role of EGFR inhibitors in nonsmall cell lung cancerFortunato Ciardiello, Ferdinando De Vita, Michele Orditura, et al.
Future Oncology (London, England)|January 11, 2018
Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistanceMustapha Tehfe, Samer Tabchi, Maria Maddalena Laterza, et al.
Journal of Radiology Case Reports|September 28, 2019
An intramedullary "flame" recognized as being an intramedullary spinal cord metastasis from esophageal cancerAssunta Grillo, Raffaella Capasso, Angelica Petrillo, et al.
Future Oncology (London, England)|March 25, 2006
Cetuximab in the treatment of colorectal cancerFortunato Ciardiello, Ferdinando De Vita, Michele Orditura, et al.
World Journal of Gastroenterology|April 28, 2015
Treatment of esophagogastric junction carcinoma: an unsolved debateMichele Orditura, Gennaro Galizia, Eva Lieto, et al.
Expert Opinion on Emerging Drugs|December 10, 2003
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trialsFortunato Ciardiello, Ferdinando De Vita, Michele Orditura, et al.
Journal of Nephrology|May 4, 2010
Genomic and proteomic approaches to renal cell carcinomaMiriam Zacchia, Annalisa Vilasi, Anna Capasso, et al.
Expert Opinion on Investigational Drugs|May 23, 2012
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancerTeresa Troiani, Erika Martinelli, Michele Orditura, et al.
Plos One|December 17, 2011
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitorsFloriana Morgillo, Erika Martinelli, Teresa Troiani, et al.
Pageof 17

Showing results (1-10 of 162) with videos related to

Sort By:
Pageof 17
Expert Opinion on Investigational Drugs|May 27, 2009
Novel investigational drugs for gastric cancerLoredana Vecchione, Michele Orditura, Fortunato Ciardiello, et al.
Current Opinion in Oncology|April 13, 2004
The role of EGFR inhibitors in nonsmall cell lung cancerFortunato Ciardiello, Ferdinando De Vita, Michele Orditura, et al.
Future Oncology (London, England)|January 11, 2018
Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistanceMustapha Tehfe, Samer Tabchi, Maria Maddalena Laterza, et al.
Journal of Radiology Case Reports|September 28, 2019
An intramedullary "flame" recognized as being an intramedullary spinal cord metastasis from esophageal cancerAssunta Grillo, Raffaella Capasso, Angelica Petrillo, et al.
Future Oncology (London, England)|March 25, 2006
Cetuximab in the treatment of colorectal cancerFortunato Ciardiello, Ferdinando De Vita, Michele Orditura, et al.
World Journal of Gastroenterology|April 28, 2015
Treatment of esophagogastric junction carcinoma: an unsolved debateMichele Orditura, Gennaro Galizia, Eva Lieto, et al.
Expert Opinion on Emerging Drugs|December 10, 2003
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trialsFortunato Ciardiello, Ferdinando De Vita, Michele Orditura, et al.
Journal of Nephrology|May 4, 2010
Genomic and proteomic approaches to renal cell carcinomaMiriam Zacchia, Annalisa Vilasi, Anna Capasso, et al.
Expert Opinion on Investigational Drugs|May 23, 2012
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancerTeresa Troiani, Erika Martinelli, Michele Orditura, et al.
Plos One|December 17, 2011
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitorsFloriana Morgillo, Erika Martinelli, Teresa Troiani, et al.
Pageof 17